Norman E. Sharpless, MD, director of the National Cancer Institute (NCI) since October 2017, has been announced as the new acting commissioner of the FDA. Sharpless replaces Scott Gottlieb, MD, who unexpectedly resigned from the position on March 5.

President Trump’s budget proposal for 2020 would negatively impact almost every institute at the NIH, including trimming the funding for the National Heart, Lung and Blood Institute by about $486 million.

A napping habit could lower blood pressure to a similar extent as other lifestyle modifications and some drugs, according to research scheduled to be presented March 18 at the American College of Cardiology’s scientific sessions in New Orleans.

The SPRINT trial suggested a more aggressive blood pressure-lowering target reduced the rate of cardiovascular events in hypertensive people, but a new secondary analysis of the trial indicates such an approach may actually be harmful for smokers.

When it comes to digital medicine, digital pathology is very late to the game. But its time is coming. And the benefits could be many: Bolstering the capabilities, efficiency and reach of individual pathologists, cutting patient wait times, streamlining multidisciplinary team meetings (MDTs) and offering more data-rich decision-making. It could even obviate a shortage of pathologists. Where does it fit into your strategic plan?

Second-opinion breast MRI reviews by subspecialized radiologists can improve patient management and increase cancer detection, according to findings published in the Journal of the American College of Radiology.

South Dakota Gov. Kristi Noem has signed the state’s breast density reporting legislation into law. The bill goes into effect on July 1.

Once a child’s broken arm is on the mend, little to nothing is gained by having follow-up x-rays read by both radiologists and orthopedic surgeons, according to a study conducted at Case Western Reserve University and published online March 6 in the Journal of Pediatric Orthopaedics.

Gadolinium-based contrast agents (GBCAs) are typically administered during follow-up imaging of multiple sclerosis (MS) patients. According to new research published in Radiology, however, unenhanced MRI scans are sufficient.

Edwards Lifesciences has invested $35 million for an exclusive right to acquire Corvia Medical, which is engaged in a U.S. pivotal trial for its InterAtrial Shunt Device (IASD) to treat heart failure.